249 related articles for article (PubMed ID: 21159664)
1. Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.
Paillas S; Boissière F; Bibeau F; Denouel A; Mollevi C; Causse A; Denis V; Vezzio-Vié N; Marzi L; Cortijo C; Ait-Arsa I; Askari N; Pourquier P; Martineau P; Del Rio M; Gongora C
Cancer Res; 2011 Feb; 71(3):1041-9. PubMed ID: 21159664
[TBL] [Abstract][Full Text] [Related]
2. MAPK14/p38α confers irinotecan resistance to TP53-defective cells by inducing survival autophagy.
Paillas S; Causse A; Marzi L; de Medina P; Poirot M; Denis V; Vezzio-Vie N; Espert L; Arzouk H; Coquelle A; Martineau P; Del Rio M; Pattingre S; Gongora C
Autophagy; 2012 Jul; 8(7):1098-112. PubMed ID: 22647487
[TBL] [Abstract][Full Text] [Related]
3. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.
Mazard T; Causse A; Simony J; Leconet W; Vezzio-Vie N; Torro A; Jarlier M; Evrard A; Del Rio M; Assenat E; Martineau P; Ychou M; Robert B; Gongora C
Mol Cancer Ther; 2013 Oct; 12(10):2121-34. PubMed ID: 23960095
[TBL] [Abstract][Full Text] [Related]
5. Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38.
Gongora C; Candeil L; Vezzio N; Copois V; Denis V; Breil C; Molina F; Fraslon C; Conseiller E; Pau B; Martineau P; Del Rio M
Cancer Biol Ther; 2008 Jun; 7(6):822-32. PubMed ID: 18340113
[TBL] [Abstract][Full Text] [Related]
6. TNF Signaling through RIP1 Kinase Enhances SN38-Induced Death in Colon Adenocarcinoma.
Cabal-Hierro L; O'Dwyer PJ
Mol Cancer Res; 2017 Apr; 15(4):395-404. PubMed ID: 28087739
[TBL] [Abstract][Full Text] [Related]
7. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
Candeil L; Gourdier I; Peyron D; Vezzio N; Copois V; Bibeau F; Orsetti B; Scheffer GL; Ychou M; Khan QA; Pommier Y; Pau B; Martineau P; Del Rio M
Int J Cancer; 2004 May; 109(6):848-54. PubMed ID: 15027118
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors.
Gupta J; Igea A; Papaioannou M; Lopez-Casas PP; Llonch E; Hidalgo M; Gorgoulis VG; Nebreda AR
Oncotarget; 2015 Apr; 6(11):8539-51. PubMed ID: 25890501
[TBL] [Abstract][Full Text] [Related]
9. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
Ravi R; Jain AJ; Schulick RD; Pham V; Prouser TS; Allen H; Mayer EG; Yu H; Pardoll DM; Ashkenazi A; Bedi A
Cancer Res; 2004 Dec; 64(24):9105-14. PubMed ID: 15604280
[TBL] [Abstract][Full Text] [Related]
10. Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.
Na YS; Kim SM; Jung KA; Yang SJ; Hong YS; Ryu MH; Ro S; Cho DH; Kim JC; Jin DH; Lee JS; Kim TW
Oncol Rep; 2010 Dec; 24(6):1509-14. PubMed ID: 21042746
[TBL] [Abstract][Full Text] [Related]
11. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
Oliver PG; LoBuglio AF; Zinn KR; Kim H; Nan L; Zhou T; Wang W; Buchsbaum DJ
Clin Cancer Res; 2008 Apr; 14(7):2180-9. PubMed ID: 18381960
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice.
Sasaki T; Kitadai Y; Nakamura T; Kim JS; Tsan RZ; Kuwai T; Langley RR; Fan D; Kim SJ; Fidler IJ
Neoplasia; 2007 Dec; 9(12):1066-77. PubMed ID: 18084614
[TBL] [Abstract][Full Text] [Related]
13. Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines.
Fischel JL; Rostagno P; Formento P; Dubreuil A; Etienne MC; Milano G
Br J Cancer; 2001 Feb; 84(4):579-85. PubMed ID: 11207057
[TBL] [Abstract][Full Text] [Related]
14. p38MAPK inhibitor SB203580 sensitizes human SNU-C4 colon cancer cells to exisulind-induced apoptosis.
Lim SJ; Lee YJ; Lee E
Oncol Rep; 2006 Nov; 16(5):1131-5. PubMed ID: 17016604
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.
Allen WL; Turkington RC; Stevenson L; Carson G; Coyle VM; Hector S; Dunne P; Van Schaeybroeck S; Longley DB; Johnston PG
Mol Cancer Ther; 2012 Aug; 11(8):1724-34. PubMed ID: 22665525
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design.
Massey AJ; Stokes S; Browne H; Foloppe N; Fiumana A; Scrace S; Fallowfield M; Bedford S; Webb P; Baker L; Christie M; Drysdale MJ; Wood M
Oncotarget; 2015 Nov; 6(34):35797-812. PubMed ID: 26437226
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells.
Davidson D; Coulombe Y; Martinez-Marignac VL; Amrein L; Grenier J; Hodkinson K; Masson JY; Aloyz R; Panasci L
Invest New Drugs; 2012 Jun; 30(3):1248-56. PubMed ID: 21221710
[TBL] [Abstract][Full Text] [Related]
18. Heparin regulates colon cancer cell growth through p38 mitogen-activated protein kinase signalling.
Chatzinikolaou G; Nikitovic D; Berdiaki A; Zafiropoulos A; Katonis P; Karamanos NK; Tzanakakis GN
Cell Prolif; 2010 Feb; 43(1):9-18. PubMed ID: 19845689
[TBL] [Abstract][Full Text] [Related]
19. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis.
Pencreach E; Guérin E; Nicolet C; Lelong-Rebel I; Voegeli AC; Oudet P; Larsen AK; Gaub MP; Guenot D
Clin Cancer Res; 2009 Feb; 15(4):1297-307. PubMed ID: 19190131
[TBL] [Abstract][Full Text] [Related]
20. Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan.
Emmink BL; Van Houdt WJ; Vries RG; Hoogwater FJ; Govaert KM; Verheem A; Nijkamp MW; Steller EJ; Jimenez CR; Clevers H; Borel Rinkes IH; Kranenburg O
Gastroenterology; 2011 Jul; 141(1):269-78. PubMed ID: 21459094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
